Human Extracellular Matrix Composition Without Animal-Derived Scaffolds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing extracellular matrix using Matrigel, derived from mouse sarcoma, pose risks of infection and immune response, necessitating a safer, self-assembling alternative.
Innovation Solution
A serum-free/xeno-free culture medium is used to culture human-derived connective tissue cells, producing extracellular matrix with matrix-bound nanovesicles that inhibit self-assembly, enhancing production and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Matrigel (mouse sarcoma-derived) is used as cell culture scaffold, then extracellular matrix can be produced, but risks of infection and heterogeneous immune response increase
Solution Approach 1:
The patent extracts and eliminates animal-derived components (mouse sarcoma) from the extracellular matrix production system, using only human-derived connective tissue cells in a serum-free/xeno-free culture medium. This removes the harmful factors (infection risk, immune response) while maintaining the desired function (ECM production).
Solution Approach 2:
The patent changes the cultural parameters by using serum-free/xeno-free culture medium instead of traditional animal serum-containing media. This parameter change eliminates harmful animal components while maintaining cell viability and ECM production capability through optimized human cell culture conditions.
2Adaptability or versatility
If Matrigel is used for organoid production, then tissue formation is enabled, but material safety and reliability are compromised
Solution Approach 1:
The patent removes the unsafe Matrigel material and replaces it with human-derived extracellular matrix produced through controlled cell culture. This extraction of harmful materials while preserving the essential function of tissue formation enables reliable and safe organoid production.
Solution Approach 2:
The patent employs a self-assembling extracellular matrix system where human connective tissue cells automatically produce and assemble ECM components in their native three-dimensional configuration. This self-assembly process eliminates the need for complex scaffold materials like Matrigel, improving both safety and reliability.
3Productivity
If conventional cell culture methods are used, then extracellular matrix can be produced, but production concentration and efficiency are insufficient
Solution Approach 1:
The patent optimizes cultural parameters by using serum-free/xeno-free medium with specific growth factors and additives, enabling high-concentration ECM production. This parameter optimization increases productivity while simplifying the manufacturing process by eliminating the need for complex animal serum preparations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method yields a high concentration of human-derived extracellular matrix free from animal components, suitable for medical and cosmetic applications, with enhanced safety and efficacy.
Implementation Method 1
it is necessary to develop a method for producing an extracellular matrix in a self-assembling form
Implementation Method 2
the presence of the extracellular matrix and matrix-bound nanovesicles inhibit self-assembly of the extracellular matrix
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
The disclosure relates to a method for preparing an extracellular matrix through the cultivation of connective tissue cells, and a use of the prepared extracellular matrix. More specifically, the disclosure relates to a method for culturing connective tissue cells using a serum-free and xenogeneic component-free culture medium, and can be effectively utilized to increase the production of extracellular matrix. Additionally, the extracellular matrix prepared by the preparation method of the disclosure is derived from human cells without the use of xenogeneic components such as fetal bovine serum, etc., and thus can be safely and effectively used in the development of medical devices for tissue therapy, including cell therapy products and medical supplies, or cosmetic raw materials.